Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058331 · ClinicalTrials.gov registry record · Phase 3
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 365
- Enrollment target
NCT00058331 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 365 participants.
The verdict
NCT00058331, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 365 participants
- Enrollment target
Study Summary
RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with solid tumors. It is not yet known whether epoetin alfa given once a week is more effective than epoetin alfa given once every 3 weeks in treating anemia. PURPOSE: Randomized phase III trial to study the effectiveness of epoetin alfa in treating anemia in patients who have solid tumors.
Interventions
- BIOLOGICAL epoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2003-06 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058331
The ClinicalTrials.gov registry entry for NCT00058331 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which epoetin alfa is the first listed.
NCT00058331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00058331 about?
NCT00058331 is a clinical study titled "Epoetin Alfa in Treating Anemia in Patients With Solid Tumors". RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with solid tumors. It is not yet known whether epoetin alfa given once a week is more effective than epoetin alfa given once every 3 weeks in treating anemia. PURPOSE: Randomized phase III trial to study th...
What is the current status of trial NCT00058331?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 365 participants. The study started on 2003-06. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00058331?
The interventions under investigation include: epoetin alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00058331?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.